Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape

Area of Science:

• Hepatology and Oncology
• Cancer Therapeutics
• Clinical Trial Design

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern with increasing incidence and high mortality.
• Sorafenib was the sole FDA-approved therapy for HCC for an extended period.
• Recent years have introduced new FDA-approved treatments, altering the therapeutic landscape.

Purpose of the Study:

• To review the evolving treatment landscape for hepatocellular carcinoma (HCC).
• To discuss the implications of new tyrosine kinase inhibitors (TKIs) and immunotherapies in HCC management.
• To highlight the critical need for optimal sequencing strategies for available HCC therapies.

Main Methods:

• Review of recent clinical trial data and FDA approvals for HCC treatments.
• Analysis of the efficacy and safety profiles of multi-targeted TKIs (lenvatinib, regorafenib) and immunotherapies (nivolumab).
• Discussion of ongoing research into treatment sequencing and novel therapeutic agents.

Main Results:

• Multiple multi-targeted TKIs, including lenvatinib and regorafenib, have gained FDA approval for first- and second-line HCC treatment.
• Immunotherapy, exemplified by nivolumab, has also shown promising results and received FDA approval.
• Significant questions remain regarding the optimal sequencing of these diverse therapeutic options.

Conclusions:

• The treatment paradigm for HCC has significantly evolved with the introduction of new TKIs and immunotherapies.
• Effective positioning and sequencing of these agents are paramount for optimizing patient outcomes.
• Further research is essential to address remaining questions and explore novel therapeutic strategies for HCC.